Document is current

Article History

First Online: 1 September 2020

Declarations

:

: No external funding was used in the preparation of this manuscript.

: Debora de Melo Gagliato, Antonio C. Buzaid, and Jose Perez-Garcia have no conflicts of interest that might be relevant to the contents of this manuscript. Javier Cortes has served as a consultant/advisor for Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceuticals, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp & Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, and Kyowa Kirin; has received honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp & Dohme, and Daiichi Sankyo; has received research funding paid to his institution from Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffmann-La Roche, Guardant Health, Merck Sharp & Dohme, Pfizer, PIQUR Therapeutics, Puma C, and Queen Mary University of London; holds stock, patents, and intellectual property with MedSIR; and has received travel, accommodation, and expenses from Roche, Novartis, Eisai, Pfizer, and Daiichi Sankyo.

: Not applicable.

: Not applicable.